^
Association details:
| Biomarker: | HOXA9 overexpression + MEIS1 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | entospletinib (GS-9973) (SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
Published date:
08/20/2020
Excerpt:
This was an international multicenter phase Ib/II study, entospletinib dose escalation (standard 3+3 design between 200 and 400 mg twice daily) + 7+3 (cytarabine + daunorubicin) in phase Ib and entospletinib dose expansion (400 mg twice daily) + 7+3 in phase II....Entospletinib with intensive chemotherapy was well-tolerated in patients with AML. Improved survival was observed in patients with HOXA9/MEIS1 overexpression...
Secondary therapy:
cytarabine + daunorubicin
DOI:
10.1158/1078-0432.CCR-20-1064
